Join China Hi-Tech Fair 2024, Where Innovation Meets Global Opportunity

22.7.2024 03:30:00 EEST | Business Wire | Press release

The 26^th China Hi-Tech Fair (CHTF) is set to take place on November 14-16, 2024, at the Shenzhen World Exhibition & Convention Center. As China’s leading and most influential technology event, CHTF offers an unparalleled platform for tech companies worldwide to showcase their latest innovations, engage with industry leaders, and expand their market reach.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240721948434/en/

Embrace Innovation, Drive Growth

Over the past 25 years, CHTF has established itself as a beacon for technological advancement and international cooperation. With this year’s theme “Technology Leads Development, Industry Integrates Fusion,” the fair underscores the critical role of innovation in driving industrial integration and economic growth.

Concurrent Events

Alongside the exhibition, a lineup of over 150 concurrent events will explore groundbreaking ideas and foster collaboration. These include:

The 7th China Green Economy Summit and Chinese Cities Investment Attracting Conference
Innovative Biological Drugs and Cell Quality Progress Forum
Molecular Diagnosis and Companion Diagnosis Summit Forum
Antibody Drugs and New Drug R&D Innovation Forum
Gene Sequencing Application Development Forum
Southern University of Science and Technology Forum
International Cross-domain Cooperation and Collaborative Development of Cross-border E-commerce Forum
China Silicon Photonics Industry Forum
AI Terminal, Intelligent Positioning System New Product Launch
2024 New Quality Productivity Summit

Unparalleled Market Access and Networking Opportunities:

Unmatched Exposure: To attract over 500,000 attendees, including 150 domestic and international delegations from 105 countries and regions.
Influential Audience: To engage with more than 10,000 technological projects and 5,000 exhibitors, including 800+ listed companies and 400+ CEOs and entrepreneurs from multinational corporations.
Media Reach: To gain extensive media coverage from over 1,500 journalists representing 200 domestic and overseas media organizations, ensuring global visibility.
Industry Leaders: To network with prominent figures such as Nobel Prize winners and top industry scholars, enhancing your brand’s credibility and influence.

CHTF is where global innovation converges, serving as a gateway to China’s booming tech market. It offers invaluable insights into market trends and fosters partnerships on a global scale, making it an unmissable event for anyone involved in the technology sector.

To register as an exhibitor, please visit here.

To register as a visitor, please visit here.

For more information, please visit www.chtf.com/english/

View source version on businesswire.com: https://www.businesswire.com/news/home/20240721948434/en/

Contacts

Media Cooperation
Ms. Ocean An
ah@zhenweiexpo.com

Booth Booking
Ms. Donna Hau
hjn@zhenweiexpo.com

Visitor Enquiry
Ms. Sarah Wang
sarah@zhenweiexpo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release

The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 15:48:00 EEST | Press release

Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong engagement across asset classes, geographies and user activity: Users from more than 180 different countries $38.4 billion in cumul

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom